Effects of an interprofessional Quality Circle-Deprescribing Module (QC-DeMo) in Swiss nursing homes: a randomised controlled trial.

Détails

Ressource 1Télécharger: 33933030_BIB_8630C265099D.pdf (921.06 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_8630C265099D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Effects of an interprofessional Quality Circle-Deprescribing Module (QC-DeMo) in Swiss nursing homes: a randomised controlled trial.
Périodique
BMC geriatrics
Auteur(s)
Cateau D., Ballabeni P., Niquille A.
ISSN
1471-2318 (Electronic)
ISSN-L
1471-2318
Statut éditorial
Publié
Date de publication
01/05/2021
Peer-reviewed
Oui
Volume
21
Numéro
1
Pages
289
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Potentially inappropriate medications (PIMs) are common among nursing homes (NH) residents, as is polypharmacy. Deprescribing has emerged in the past decade as a safe and effective way to reduce the use of PIMs and improve patient outcomes. However, effective deprescribing interventions are expensive, as they require specialised staff and a great amount of time for each resident. The Quality Circle Deprescribing Module (QC-DeMo) intervention was designed to be less resource-intensive than medication reviews, the current deprescribing gold standard. It consists of a QC session in which physicians, nurses, and pharmacists define a local deprescribing consensus for specific PIMs classes, which is then implemented in the NH. The intervention was trialled in a RCT, with the NH as unit of analysis.
After randomisation, intervention NHs enacted the QC-DeMo at the start of the follow-up year. The primary outcomes were the proportion of PIM galenic units and number of PIM defined daily dose per average resident and per day (DDD/res). PIM status was assessed by a combination of the 2015 Beers list and the Norwegian General Practice-Nursing Home criteria. Secondary outcomes were the number of DDD/res to avoid and to reevaluate; safety outcomes were mortality, hospitalisations, falls, and use of physical restraints. Outcomes were evaluated at follow-up using linear regression models, adjusting for the outcome baseline values.
Fifty-eight NHs took part in the trial; no individual residents were recruited. The intervention did not reduce the primary outcomes, but a strong trend towards reduction was seen for the number of PIM DDD/res, which accounts for the doses used. PIM DDD/res to reevaluate were significantly reduced, mostly through a reduction in the use of proton-pump inhibitors. Falls and use of physical restraints were not affected, but a statistical interaction between the mission of the NH (geriatric unit or specialised dementia unit) and the intervention group was seen for mortality and hospitalisations.
The QC-DeMo intervention can reduce the use of some PIM classes, and could usefully complement other deprescribing interventions.
ClinicalTrials.gov ( NCT03688542 ), registered on 26.09.2018, retrospectively registered.
Mots-clé
Collaboration, Deprescribing, Nursing home, Potentially inappropriate medications, Quality circle
Pubmed
Open Access
Oui
Création de la notice
19/05/2021 12:25
Dernière modification de la notice
12/01/2022 7:11
Données d'usage